Cost-effectiveness of pulmonary resection and systemic chemotherapy in the management of metastatic soft tissue sarcoma: A combined analysis from the University of Texas M. D. Anderson and Memorial Sloan-Kettering Cancer Centers

Journal of Thoracic and Cardiovascular Surgery

Volumn 127, Issue 5, 2004, Pages 1366-1372

  Porter, Geoffrey A ^a   Cantor, Scott B ^b   Walsh, Garrett L ^b   Rusch, Valerie W ^c   Leung, Dennis H ^d   DeJesus, Alma Y ^b   Pollock, Raphael E ^b   Brennan, Murray F ^c   Pisters, Peter W T ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; IFOSFAMIDE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; LUNG METASTASIS; LUNG RESECTION; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SOFT TISSUE SARCOMA; TREATMENT OUTCOME; UNITED STATES; UNIVERSITY HOSPITAL;

EID: 2342420027     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2003.11.016     Document Type: Article

References (33)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics 2002. CA Cancer J Clin. 2002;52:23-47.
2. Potter DA, Glenn J, Kinsella EJ, et al. Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J Clin Oncol. 1985;3:353-66.
3. Gadd MA, Casper ES, Woodruff JM, et al. Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Ann Surg. 1993;218:705-12.
4. Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft-tissue sarcoma: analysis of patterns of disease and postmetastasis survival. Ann Surg. 1999;229:602-12.
5. Jablons D, Steinberg SM, Roth J, et al. Metastasectomy for soft tissue sarcoma. J Thorac Cardiovasc Surg. 1989;97:695-705.
6. Van Geel AN, Pastorino U, Jauch KW, et al. Surgical treatment of lung metastases: the European Organization for the Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer. 1996;77:675-82.
7. Verazin GT, Warneke JA, Driscoll DL, et al. Resection of lung metastases from soft-tissue sarcomas: a multivariate analysis. Arch Surg. 1992;127:1407-11.
8. Casson AG, Putnam JB, Natarajan G, et al. Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma. Cancer. 1992;69:662-8.
9. Vogt-Moykopf I, Krysa S, Bulzebruck H, et al. Surgery for pulmonary metastases: the Heidelberg experience. Chest Surg Clin North Am. 1994;4:85-112.
10. Robinson MH, Sheppard M, Moscovic E, et al. Lung metastasectomy in patients with soft tissue sarcoma. Br J Radiol. 1994;67:129-35.
11. Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113:37-49.
12. Temple LK, Brennan MF. The role of pulmonary metastasectomy in soft tissue sarcoma. Semin Thorac Cardiovasc Surg. 2002;114:35-44.
13. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol. 1999;17:150-9.
14. Demetri GD, Delaney T. NCCN: sarcoma. Cancer Control. 2001;8:94-101.
15. Mentzer SJ, Antman KH, Attinger C, et al. Selected benefits of thoracotomy and chemotherapy for sarcoma metastatic to the lung. J Surg Oncol. 1993;53:54-9.
16. Pastorino U. Metastasectomy for soft tissue sarcomas. In: Verweij J, Pinedo HM, Suit HD, editors. Soft tissue sarcomas: present achievements and future prospects. Boston: Kluwer Academic Publishers; 1997. p. 65-75.
17. Baxter G, Alvegard TA, Monge O. VIG chemotherapy in advanced soft tissue sarcoma - results of the Scandinavian Sarcoma Group SSG-X trial. Acta Orthop Scand Suppl. 1995;265:93-4.
18. Detsky AS, Krahn M, Naglie G, et al. Primer on medical decision analysis: part 2. Tree structures. Med Decis Making. 1997;17:126-35.
19. Cantor SB. Decision analysis: theory and application to medicine. Prim Care. 1995;22:261-70.
20. Tengs TO, Adams ME, Plisken JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15:369-90.
21. Gold MR, Seigel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
22. Williard WC, Collin C, Casper ES, et al. The changing role of amputation for soft-tissue sarcoma of the extremity in adults. Surg Gynecol Obstet. 1992;175:389-96.
23. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol. 2003;15:2719-25.
24. Pisters PWT, Harrison LB, Leung JM, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14:859-68.
25. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196:305-15.
26. Lewis JJ, Leung DHY, Casper ES, et al. Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. Arch Surg. 1999;134:199-204.
27. Tierney JF. Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997;350:1647-54.
28. Finkler SA. The distinction between cost and charges. Ann Intern Med. 1982;96:102-9.
29. McLeod RS. Quality of life, nutritional status and gastrointestinal hormone profile following the Whipple procedure. Ann Oncol. 1999; 10(suppl):281-4.
30. Kulaksizoglu H, Toktas G, Kulaksizoglu I, et al. When should quality of life be measured after radical cystectomy? Eur Urol. 2002;42:350-7.
31. Hillner BE, Kirkwood JM, Atkins MB, et al. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol. 1997;15:2351-8.
32. Dowling RD, Landreneau RJ, Miller DL. Video-assisted thoracoscopic surgery for resection of lung metastases. Chest. 1998;113(1 suppl):2S-5S.
33. McCormack PM, Bains MS, Begg CB, et al. Role of video-assisted surgery in the treatment of pulmonary metastases: results of a prospective trial. Ann Thorac Surg. 1996;62:213-6.